Biotech Pipelines: Prices Never Lower
Pharmaceutical companies love to deals early, at R&D stage, or late, when products are ready to be marketed. But they hate doing deals in the middle. Why? The risk to too high. Everyone knows what to expect from late stage deals; and no one's going to get killed for an early-stage deal that goes wrong. But Phase I and II deals often carry high price tags and chancy pay-offs.
You may also be interested in...
Managed Care Tackles Biotech Blockbusters
Manufacturers in the past haven't paid much heed to health plans' half-hearted efforts to reign in biotech drug spending. They figure if the drug is good enough, payers have to cover it. But health plans are for the first time serious about managing specialty pharma spending. Manufacturers should take heed because the impact on their revenues and marketing strategies could be significant.
Diabetes Drugs: US FDA Proposes Hypoglycemia Efficacy Endpoints, With Limits
Reduction in the risk of hypoglycemia level 2 and 3 events, along with either a reduction or maintenance of an acceptable hemoglobin A1C, is a clinically relevant efficacy endpoint for drug development in Types 1 and 2 diabetes, FDA states in new draft guidance.
Health And Wellness Executive Decisions: NIH ODS Director, B+L Consumer Chief, Herbalife, More
Army Institute Performance Division physiologist leads NIH ODS; Ferris heads B+L consumer products; medical director For HumanN supplements; and Herbalife scores Ronaldo sponsorship extension.